Clinical Trials Network New England Consortium Node: Admin Supplement CTN0131

临床试验网络新英格兰联盟节点：管理补充 CTN0131

• 批准号: 10655837
• 负责人: Gail D'Onofrio
• 金额: $ 163.84万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10655837
• 关键词: Buprenorphine; Clinical Trials Network; Effectiveness; Health system; Hybrids; Methadone; New England; Participant; Patients; Pharmaceutical Preparations; Pharmacy Administration; Provider; Randomized; Site; base; comparative effectiveness; implementation barriers; implementation facilitators; opioid use disorder

We will conduct a randomized, pragmatic hybrid type 1 effectiveness/implementation multisite (approximately 6 sites) trial to determine whether office-based methadone with pharmacy administration and/or dispensing or buprenorphine (BUP) results in greater treatment retention in approximately 600 patients with opioid use disorder (OUD) not optimally benefiting from office-based BUP. As part of the trial, we will identify implementation barriers and facilitators at the patient, provider and health-systems level for office-based methadone with pharmacy administration and/or dispensing.

我们将进行一项随机、务实的混合1型有效性/实施多站点（约6 研究中心）试验，以确定是否可以通过药房给药和/或配药来使用基于办公室的美沙酮，或者 丁丙诺啡（BUP）在约600例阿片类药物使用障碍患者中导致更大的治疗保留 (OUD)没有最佳地受益于基于办公室的BUP。作为试验的一部分，我们将确定实施障碍 以及在病人、提供者和卫生系统一级为诊所提供美沙酮和药房的促进者 给药和/或分配。